DUKE ENERGY CORP (DUK)
Sector: Utilities
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Utilities
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for DUK
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| DUK | Chairman and CEO; Independent Director Nominee | 59 | ["Chairman and CEO, Merck & Co., Inc.", "Chairman and CEO, Merck & Co. Inc.", "Director of Duke Energy since 2018", "significant experience in regulatory matters", "experience in finance and risk management", "legal knowledge with Doctor of Jurisprudence", "experience with technology and cybersecurity", "oversight of enterprise risk management as CFO at Merck", "experience in management and finance roles at Baxter International"] | ["Corporate Governance Committee", "Finance and Risk Management Committee (Chair)"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MRK | Chairman, Chief Executive Officer and President, Merck & Co., Inc. | 58 | ["extensive management, financial, and operational expertise","previously served as Merck’s President","responsibility for Merck’s operating divisions","served as Merck’s Chief Financial Officer","Executive Vice President, Global Services","experience on governance issues facing public companies"] | ["Finance & Risk Management Committee","Corporate Governance Committee"] | 2025 |
Biography sourced from the proxy statement filing.
Robert M. Davis has been Chairman of the Board of Merck since December 2022 and CEO of Merck since July 2021. Prior to that time, Mr. Davis served as Merck s President from April 2021 until June 2021, responsible for the company s operating divisions Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was Executive Vice President, Global Services since 2016, with responsibility for information technology and procurement, and Merck s CFO since April 2014, with additional responsibility for real estate operations, corporate strategy, and business development. Prior to joining Merck, Mr. Davis was Corporate Vice President and President of Baxter International Inc. s medical products business. During his tenure at Baxter, he held several other positions, including President of Baxter s renal business, CFO, and Treasurer. Before joining Baxter in 2004, Mr. Davis held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company. Mr. Davis qualifications for election include his significant experience in regulatory matters, finance, and risk management obtained during his service as the Chairman and CEO of Merck and as CFO prior to that. During his service as CFO, enterprise risk management and finance were within his areas of responsibility. In addition, he gained significant experience in these areas, while serving in a variety of management and finance roles at Baxter International. Mr. Davis legal knowledge, obtained when he earned his Doctor of Jurisprudence, adds additional insight to the Board s discussions of legal and risk issues. Mr. Davis also has significant experience with technology and cybersecurity as a result of his direct oversight of those areas during his time as CFO of Merck and at Baxter International. Mr. Davis experience at Merck provides valuable insight into navigating an industry undergoing rapid transformation.